Replies to post #160553 on Biotech Values

[jq1234]

PFE: What was the reason for 19% YOY decline of Prevnar in US?

[DewDiligence]

PFE and The Global Demographic Tailwind:

http://finance.yahoo.com/news/pfizers-ceo-discusses-q1-2013-165608862.html

During the first quarter, biopharmaceutical volume [grew]10% in the BRIC-MT* markets…primarily driven by strong growth in China and partially offset by price reductions of 1% to these markets…

If you exclude the product portfolio of products whose rights were transferred to our joint venture in China with Hisun, our operational revenue growth would have been 8% in our emerging markets business, 14% in BRIC-MT countries and 31% in China.

*Brazil, Russia, India, China, Mexico, Turkey.

[dav1234]

Pfizer (PFE) plans to spin off its remaining stake in Zoetis (ZTS) through a tax-free exchange offer in which Pfizer owners can exchange their Pfizer shares for stock in Zoetis owned by Pfizer (got that?). Pfizer has received a waiver of the 180-day lock-up from the book runners of the Zoetis IPO. PFE +2.1%, ZTS -1.2% premarket.

http://seekingalpha.com/news-article/6625001-pfizer-announces-plan-for-split-off-of-zoetis